about
Non-synonymous polymorphisms in the FCN1 gene determine ligand-binding ability and serum levels of M-ficolinCRP genotype and haplotype associations with serum C-reactive protein level and DAS28 in untreated early rheumatoid arthritis patientsmiR-155 as a Biomarker in B-Cell MalignanciesMicroRNAs in B-cells: from normal differentiation to treatment of malignanciesThe myeloma stem cell concept, revisited: from phenomenology to operational termsProof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myelomaA model system for assessing and comparing the ability of exon microarray and tag sequencing to detect genes specific for malignant B-cells.Polymorphisms in the MASP1 gene are associated with serum levels of MASP-1, MASP-3, and MAp44Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysisExposure time independent summary statistics for assessment of drug dependent cell line growth inhibition.Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosisLong Noncoding RNA Expression during Human B-Cell DevelopmentUnaccounted uncertainty from qPCR efficiency estimates entails uncontrolled false positive rates.Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma Patients.Retinal proteome changes following experimental branch retinal vein occlusion and intervention with ranibizumab.hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision MedicineNeutrophil Extracellular Traps in Ulcerative Colitis: A Proteome Analysis of Intestinal Biopsies.Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human MucosaMolecular classification of tissue from a transformed non-Hogkin's lymphoma case with unexpected long-time remission.Cell of origin associated classification of B-cell malignancies by gene signatures of the normal B-cell hierarchy.Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma.Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma.Validation and implementation of a method for microarray gene expression profiling of minor B-cell subpopulations in manProteome Analysis of Rheumatoid Arthritis Gut Mucosa.Inherited variation in immune response genes in follicular lymphoma and diffuse large B-cell lymphoma.MicroRNAs as novel biomarkers in diffuse large B-cell lymphoma--a systematic review.Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.The application of human phase 0 microdosing trials: A systematic review and perspectives.Alternative pre-mRNA splicing leads to potential biomarkers in diffuse large B-cell lymphoma - a systematic review.High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.Incidence of venous thromboembolism in patients with diffuse large B-cell lymphoma.The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.Stable phenotype of B-cell subsets following cryopreservation and thawing of normal human lymphocytes stored in a tissue biobank.Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement.Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP.Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study.Anthropometrics and prognosis in diffuse large B-cell lymphoma: a multicentre study of 653 patients.No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.
P50
Q21133812-0D8FDBE3-AAF9-4F40-BDA5-D1AFFB705191Q22000579-693ABE9D-0486-4D62-9E48-82E997135F05Q26746573-24D65C8C-F376-42EF-853D-365BE0FE9EBBQ26824682-F84DFAB3-F631-4075-B57B-F94F5CE7ACA4Q28076070-991C4F7F-498B-41C3-9D48-B272225C590AQ28537857-F521F819-0693-487F-AB15-D4387BD3475CQ34467490-07EBD282-EA8D-4B7B-B28E-3D30D27B0253Q34984382-FB2FF583-7D0B-4B06-BBA4-DF21FB561E99Q35023376-E7D25BD6-55AE-4838-8E2C-D76D6E9CBF14Q35182422-934864A6-0635-4AD3-B699-DA3FE65E1046Q35402899-58AB976C-8C65-4EE0-94DE-4E87EE11FB1FQ35419876-C58FA2E6-DCC2-4A6F-9FA4-011129E1D0CCQ35783785-D794B101-6A71-4472-8BC6-567A5AF4CB58Q35986454-55065472-1EDD-4B69-9A38-D044B473CC4FQ35998168-33AE789E-6AE1-4024-8707-733949BC8DB8Q36130503-5619D4FD-545B-41A2-97B2-DCCBB929D06CQ36152713-C27B7581-D870-46C3-8C8C-9D8B966731F8Q36155966-499A34B5-3092-4A78-ACFD-9F7EED2ADD85Q36239520-ECDE9993-9E54-466A-AEBE-0F34F888F7C7Q37579101-E1CADD68-6859-429B-832F-211AEC2434A7Q38133611-AA884DF3-1956-4144-833D-07B7FC421936Q38184954-EBB07376-67C4-43DE-9887-F659B8827D2BQ38235060-77FDA1C8-168D-449E-A049-5DC0116A5BCAQ38309297-9FE49093-A01D-429E-B1A1-D904CD09A592Q38387550-31E91116-9F7B-46BA-9B94-EA3B4FE846FAQ38516259-22149FC3-1238-4A9F-9EB0-3E352B4A84AFQ38518960-F270B46F-D453-4322-9C0B-1863E171CDA5Q38552173-94C4F27C-600A-44C5-A498-02AD65742314Q38597205-CF50141D-4BC2-4E68-AF95-62DB7333FE1FQ38756597-FFB9810F-1268-4CF3-B17D-CD76C6A267B5Q38795727-1F475041-7E21-4D8A-8292-1C1183796435Q38856366-542C6375-AAC3-4A7C-9D46-10154C8A4342Q38941888-5674044E-E9CF-4F73-8CA3-DE7AF0D98E2BQ39111039-EF73A868-C4DB-4D5A-BA8C-0746D6FB9A20Q39342393-BD1AE2FA-D515-4585-A09E-A21B1E5BC9FDQ39753010-7F222E3D-8EAC-403A-A3D1-D4E45A33E667Q40377586-2F861997-36A5-40B8-8CA3-E84D5F258315Q40454267-5BF063BA-7650-4148-8D3E-7F2C412BBDE2Q40929122-4257F30C-E234-493A-9EA3-860DA57B46F7Q41260547-DCA9D700-DE00-403B-B12D-AEBAC2BA1DAC
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Martin Bøgsted
@ast
Martin Bøgsted
@en
Martin Bøgsted
@es
Martin Bøgsted
@fr
Martin Bøgsted
@nl
Martin Bøgsted
@sl
type
label
Martin Bøgsted
@ast
Martin Bøgsted
@en
Martin Bøgsted
@es
Martin Bøgsted
@fr
Martin Bøgsted
@nl
Martin Bøgsted
@sl
prefLabel
Martin Bøgsted
@ast
Martin Bøgsted
@en
Martin Bøgsted
@es
Martin Bøgsted
@fr
Martin Bøgsted
@nl
Martin Bøgsted
@sl
P106
P21
P2456
P31
P496
0000-0001-9192-1814